Bionano Genomics Inc. [BNGO] Director makes an insider purchase of 10,000 shares worth 16000.0.

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Bionano Genomics Inc. shares valued at $16,000 were purchased by BARKER DAVID L on May 16. At $1.60 per share, BARKER DAVID L acquired 10,000 shares. The insider’s holdings grew to 13,894 shares worth approximately $32650.9 following the completion of this transaction.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Also, Holmlin R. Erik purchased 5,025 shares, netting a total of over 20,037 in proceeds. Following the buying of shares at $3.99 each, the insider now holds 5,025 shares.

Analysts at BTIG Research started covering the stock with ‘”a Buy”‘ outlook in a report released in mid June. As of September 24, 2020, Ladenburg Thalmann has initiated its “Buy” rating for BNGO. Earlier on April 08, 2020, Oppenheimer initiated its rating. Their recommendation was “an Outperform” for BNGO stock.

Analyzing BNGO’s Price Performance

On Thursday, Bionano Genomics Inc. [NASDAQ: BNGO] rose 3.98% to $2.35. The stock’s lowest price that day was $2.21, but it reached a high of $2.37 in the same session. During the last five days, there has been a surge of approximately 23.68%. Over the course of the year, Bionano Genomics Inc. shares have dropped approximately -21.40%. Shares of the company reached a 52-week high of $3.27 on 01/03/22 and a 52-week low of $1.16 on 05/12/22. A 50-day SMA is recorded $1.64, while a 200-day SMA reached $2.55. Nevertheless, trading volume fell to 9.73 million shares from 10.63 million shares the previous day.

Support And Resistance Levels for Bionano Genomics Inc. (BNGO)

According to the 24-hour chart, there is a support level at 2.25, which, if violated, would cause prices to drop to 2.15. In the upper region, resistance lies at 2.41. The next price resistance is at 2.47. RSI (Relative Strength Index) is 73.14 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.34, which suggests the price will decrease in the coming days. Percent R is at 6.82%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.

Is Bionano Genomics Inc. subject to short interest?

Stocks of Bionano Genomics Inc. saw a sharp rise in short interest on Jul 14, 2022 jumping by 6.12 million shares to 44.17 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 38.05 million shares. A jump of 13.86% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 7.55 of the overall float, the days-to-cover ratio (short ratio) jumped to 7.55.

Which companies own the most shares of Bionano Genomics Inc. (BNGO)?

According to BlackRock Fund Advisors filings, the company currently owns 16,416,245 shares, which is about 5.67% of the total BNGO shares outstanding. The investor’s shares have plunged by -192,762 from its previous 13-F filing of 16609007.0 shares. With the completion of the buy transaction, The Vanguard Group, Inc.’s stake is now worth $20,918,208. SSgA Funds Management, Inc. acquire a 7.30% interest valued at $10.66 million while Geode Capital Management LLC sold a -322,149 stake. A total of -73,822 shares of Bionano Genomics Inc. were sold by Northern Trust Investments, Inc. during the quarter, and 59,214 were bought by Charles Schwab Investment Managem. In its current portfolio, Morgan Stanley & Co. LLC holds 1,990,243 shares valued at $2.75 million.

In terms of Bionano Genomics Inc. share price expectations, FactSet research, analysts set an average price target of $8.67 in the next 12 months, up nearly 253.98% from the previous closing price of $2.26. Analysts anticipate Bionano Genomics Inc. stock to reach $12.00 by 2022, with the lowest price target being $6.00. In spite of this, 3 analysts ranked Bionano Genomics Inc. stock as a Buy at the end of 2022.

LEAVE A REPLY

Please enter your comment!
Please enter your name here